

# Lao PDR Support for Pneumococcal Vaccine

## This Decision Letter sets out the Programme Terms of a Programme.

2.	Grant number: 17-LAO-12c-X / /					
3.	Date of Decision Letter: December 16, 2016					
4.	Date of the Partnership Framework Agreement: June 7, 2013					
5.	Programme title: New Vaccine Support (NVS), Pneumococcal Routine					
6. \	Vaccine type: Pneumococcal					
	Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID					
8.	Programme duration <sup>1</sup> : 2013 -2017					
	Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
				2017	Total <sup>2</sup>	
		2013-2016				
	mme Budget	7,166,7	903 1,	186,000	8,352,790	
Program (US\$)	Vaccine introducti	7,166,7	<b>5\$):</b> Not applica	186,000	8,352,790	
Program (US\$)	Vaccine introducti	7,166,7	<b>5\$):</b> Not applica	186,000		
Program (US\$)	Vaccine introduction	7,166,7	<b>5\$):</b> Not applica	able	8,352,790	
Program (US\$)  10. 1  Type of swith Gave	Vaccine introduction Indicative Annual A Agreement) <sup>4</sup> supplies to be purchy funds in each yea	7,166,7	S\$): Not application in the serments of the terms	able	8,352,790 Inership Framework	
Program (US\$)  10. 1  Type of with Gaw	Vaccine introduction Indicative Annual A Agreement)4 supplies to be purch	7,166,7	S\$): Not application in the serments of the terms	able	8,352,790	
Program (US\$)  10. V  11. I  Type of with Gav Number doses	Vaccine introduction Indicative Annual A Agreement) <sup>4</sup> supplies to be purchy funds in each yea	7,166,7	S\$): Not application in the serments of the terms	able s of the Part	8,352,790 Inership Framework	

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the Programme.

2 Chemin des Mines 1202 Geneva. Switzerland Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50

<sup>&</sup>lt;sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>&</sup>lt;sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>&</sup>lt;sup>4</sup> This is the amount that Gavi has approved.

<sup>&</sup>lt;sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

### 13. Self-procurement: Not applicable

### 14. Co-financing obligations: Reference code: 17-LAO-12c-X-C

According to the co-financing policy, the Country falls within the group Accelerated transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with	2017
Country funds in each year	
Number of vaccine doses	34,900
Number of AD syringes	35,800
Number of re-constitution syringes	
Number of safety boxes	400
Value of vaccine doses (US\$)	115,070
Total co-financing payments (US\$) (including freight)	122,500

### 15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by.

On behalf of Gavi Hind Khatib-Othman

Managing Director, Country Programmes

December 16, 2016